Among those with medium to low levels of Tau (n = 1182), the primary endpoint, measured by the integrated Alzheimer’s Disease Rating Scale (iADRS), showed that Donanemab slowed cognitive decline by 35% (p < 0.001). This evidence concerns the gene MAPT and Alzheimer disease.